Publications by authors named "Laurence Willemot"
Cancers (Basel)
September 2023
Article Synopsis
- Nivolumab is now an approved immunotherapy for adjuvant treatment in patients with completely resected stage III or IV melanoma, and the PRESERV MEL study seeks to evaluate its real-world effectiveness and safety in Belgium and Luxembourg.*
-
- The study enrolled 152 patients over a 2-year period and includes both prospective and retrospective data, with key outcomes measured over a follow-up duration of at least 11.4 months.*
-
- Results show that at 12 and 18 months, the relapse-free survival rates were 74.7% and 68.4%, indicating promising initial outcomes for patients treated with nivolumab.*
